|
Speciality Spotlight
Lamivudine,
HBV Infection
-
C-L Lai, for the Asia Hepatitis Lamivudine Study Group (Queen Mary Hosp, Hong Kong, China): A One-Year Trial of Lamivudine for Chronic Hepatitis B.
N. Engl J Med, 339:61-68, 1998.
Interferon-a, now the only treatment specifically approved for hepatitis B infection causing chronic hepatitis B is least effective in Asian patients, who form the largest number of hepatitis B infection. In a one-year double-blind trial using Lamivudine in Chinese patients, there was substantially histologic improvement in many patients. Dosage of Lamivudine was 100mg daily.